Modulating YAP and TAZ activities could benefit patients with EPC dysfunction, such as patients suffering from diabetes mellitus or other vascular diseases, to enhance EPC functions and promote neovascularization in their ischemic or injured tissues [34,35]. Here, WWTR1 is linked to diabetes mellitus.